Morgan Stanley lowered the firm’s price target on Elanco (ELAN) to $13 from $14 and keeps an Equal Weight rating on the shares. Q4 EPS of 14c ...
Elanco Animal Health inks agreement with Medgene to commercialize highly pathogenic avian influenza vaccine in dairy cattle: Greenfield, Indiana Wednesday, February 26, 2025, 15:0 ...
Elanco's Q4 revenue reached $1.02 billion, topping estimates, but EPS missed forecasts. 2025 guidance lags consensus as currency headwinds pose a $110 million challenge.
Barclays lowered the firm’s price target on Elanco (ELAN) to $19 from $20 and keeps an Overweight rating on the shares. The firm sees a “solid ...
Elanco Animal Health will commercialize an avian flu vaccine for dairy cattle after reaching an agreement with Medgene.
A global manufacturer acquired a Shawnee facility in the fall, the third time it and its 300 employees have changed hands ...
Elanco Animal Health (NYSE:ELAN) traded lower in the premarket on Tuesday after the veterinary product maker, with its Q4 2024 results, set its full-year outlook below consensus, citing an unfavorable ...
Elanco Animal Health narrowed its fourth-quarter loss despite lower sales, but its forecast for the current quarter and full year came in below Wall Street's estimates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback